Literature DB >> 15591519

Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury.

S Sanz1, J B Pucilowska, S Liu, C M Rodríguez-Ortigosa, P K Lund, D A Brenner, C R Fuller, J G Simmons, A Pardo, M-L Martínez-Chantar, J A Fagin, J Prieto.   

Abstract

BACKGROUND/AIM: Hepatic stellate cells (HSCs) express alpha-smooth muscle actin (alphaSMA) and acquire a profibrogenic phenotype upon activation by noxious stimuli. Insulin-like growth I (IGF-I) has been shown to stimulate HSCs proliferation in vitro, but it has been reported to reduce liver damage and fibrogenesis when given to cirrhotic rats.
METHODS: The authors used transgenic mice (SMP8-IGF-I) expressing IGF-I under control of alphaSMA promoter to study the influence of IGF-I synthesised by activated HSCs on the recovery from liver injury.
RESULTS: The transgene was expressed by HSCs from SMP8-IGF-I mice upon activation in culture and in the livers of these animals after CCl4 challenge. Twenty four hours after administration of CCl4 both transgenic and wild type mice showed similar extensive necrosis and increased levels of serum transaminases. However at 72 hours SMP8-IGF-I mice exhibited lower serum transaminases, reduced hepatic expression of alphaSMA, and improved liver morphology compared with wild type littermates. Remarkably, at this time all eight CCl4 treated wild type mice manifested histological signs of liver necrosis that was severe in six of them, while six out of eight transgenic animals had virtually no necrosis. In SMP8-IGF-I mice robust DNA synthesis occurred earlier than in wild type animals and this was associated with enhanced production of HGF and lower TGFbeta1 mRNA expression in the SMP8-IGF-I group. Moreover, Colalpha1(I) mRNA abundance at 72 hours was reduced in SMP8-IGF-I mice compared with wild type controls.
CONCLUSIONS: Targeted overexpression of IGF-I by activated HSCs restricts their activation, attenuates fibrogenesis, and accelerates liver regeneration. These effects appear to be mediated in part by upregulation of HGF and downregulation of TGFbeta1. The data indicate that IGF-I can modulate the cytokine response to liver injury facilitating regeneration and reducing fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15591519      PMCID: PMC1774353          DOI: 10.1136/gut.2003.024505

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  43 in total

1.  Insulin-like growth factors stimulate expression of hepatocyte growth factor but not transforming growth factor beta1 in cultured hepatic stellate cells.

Authors:  S Skrtic; V Wallenius; S Ekberg; A Brenzel; A M Gressner; J O Jansson
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

2.  Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice.

Authors:  J Wang; W Niu; Y Nikiforov; S Naito; S Chernausek; D Witte; D LeRoith; A Strauch; J A Fagin
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

3.  In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis.

Authors:  J George; D Roulot; V E Koteliansky; D M Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

4.  Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis.

Authors:  A Picardi; A C de Oliveira; B Muguerza; A Tosar; J Quiroga; I Castilla-Cortázar; S Santidrián; J Prieto
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

5.  Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis.

Authors:  Y Matsuda; K Matsumoto; A Yamada; T Ichida; H Asakura; Y Komoriya; E Nishiyama; T Nakamura
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

6.  Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses.

Authors:  Z Shi; A E Wakil; D C Rockey
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

7.  Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis.

Authors:  I Castilla-Cortazar; M Garcia; B Muguerza; J Quiroga; R Perez; S Santidrian; J Prieto
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

8.  Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture.

Authors:  D C Rockey; J K Boyles; G Gabbiani; S L Friedman
Journal:  J Submicrosc Cytol Pathol       Date:  1992-04

9.  Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells.

Authors:  A M Gressner; B Lahme; A Brenzel
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

10.  Characterization of insulin-like growth factor (IGF)-I-receptor binding sites during in vitro transformation of rat hepatic stellate cells to myofibroblasts.

Authors:  A Brenzel; A M Gressner
Journal:  Eur J Clin Chem Clin Biochem       Date:  1996-05
View more
  37 in total

Review 1.  Insulin-like growth factors in the gastrointestinal tract and liver.

Authors:  John F Kuemmerle
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-15       Impact factor: 4.741

2.  Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C.

Authors:  Jose Tadeu Stefano; Maria Lucia Correa-Giannella; Cristiane Maria Freitas Ribeiro; Venancio Avancini Ferreira Alves; Paulo Celso Bosco Massarollo; Marcel Cerqueira Cesar Machado; Daniel Giannella-Neto
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

3.  Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration.

Authors:  Fatima Teixeira-Clerc; Marie-Pierre Belot; Sylvie Manin; Vanessa Deveaux; Thomas Cadoudal; Marie-Noele Chobert; Alexandre Louvet; Andreas Zimmer; Thierry Tordjmann; Ariane Mallat; Sophie Lotersztajn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

4.  The identification of stem cells in human liver diseases and hepatocellular carcinoma.

Authors:  Joan Oliva; Barbara A French; X Qing; Samuel W French
Journal:  Exp Mol Pathol       Date:  2010-01-18       Impact factor: 3.362

5.  Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy.

Authors:  Liping Zhang; Xiaonan H Wang; Huiling Wang; Jie Du; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

6.  Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells.

Authors:  Aleksandar Sokolović; Milka Sokolović; Willem Boers; Ronald Pj Oude Elferink; Piter J Bosma
Journal:  Fibrogenesis Tissue Repair       Date:  2010-02-17

7.  Effects of maternal global nutrient restriction on fetal baboon hepatic insulin-like growth factor system genes and gene products.

Authors:  Cun Li; Natalia E Schlabritz-Loutsevitch; Gene B Hubbard; Victor Han; Karen Nygard; Laura A Cox; Thomas J McDonald; Peter W Nathanielsz
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

Review 8.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

9.  Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El-Bassiouny; Mona M K Zoheiry; Mona M F Nosseir; Eman G El-Ahwany; Raafat A Ibrahim; Nora E I El-Bassiouni
Journal:  MedGenMed       Date:  2007-08-28

10.  Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner.

Authors:  Severa Bunda; Peter Liu; Yanting Wang; Kela Liu; Aleksander Hinek
Journal:  Am J Pathol       Date:  2007-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.